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OBJECTIVES: Pancreatic intraductal papillary mucinous neoplasias (IPMNs) represent 25% of all cystic neoplasms and are
precursor lesions for pancreatic ductal adenocarcinoma. This study aims to identify the best imaging modality for detecting
malignant transformation in IPMN, the sensitivity and specificity of risk features on imaging, and the usefulness of tumor markers
in serum and cyst fluid to predict malignancy in IPMN.
METHODS: Databases were searched from November 2006 to March 2014. Pooled sensitivity and specificity of diagnostic
techniques/imaging features of suspected malignancy in IPMN using a hierarchical summary receiver operator characteristic
(HSROC) approach were performed.
RESULTS: A total of 467 eligible studies were identified, of which 51 studies met the inclusion criteria and 37 of these were
incorporated into meta-analyses. The pooled sensitivity and specificity for risk features predictive of malignancy on computed
tomography/magnetic resonance imaging were 0.809 and 0.762 respectively, and on positron emission tomography were 0.968 and
0.911. Mural nodule, cyst size, and main pancreatic duct dilation found on imaging had pooled sensitivity for prediction of malignancy
of 0.690, 0.682, and 0.614, respectively, and specificity of 0.798, 0.574, and 0.687. Raised serum carbohydrate antigen 19-9 (CA19-9)
levels yielded sensitivity of 0.380 and specificity of 0903. Combining parameters yielded a sensitivity of 0.743 and specificity of 0.906.
CONCLUSIONS: PET holds the most promise in identifying malignant transformation within an IPMN. Combining parameters
increases sensitivity and specificity; the presence of mural nodule on imaging was the most sensitive whereas raised serum CA19-
9 (437 KU/l) was the most specific feature predictive of malignancy in IPMNs.
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INTRODUCTION
Intraductal papillary mucinous neoplasias (IPMNs) of the
pancreas represent 25% of all cystic neoplasms,1 with an
assumed incidence of 0.8 per 100,000.2 In 2006, the
International Consensus guidelines raised the awareness of
IPMN and for the first time defined management;3 latterly,
these guidelines have been updated.4 IPMNs of both the main
pancreatic duct (MD-IPMNs) and the branch ducts (BD-
IPMNs) are often diagnosed incidentally by cross-sectional
imaging5–7 undertaken to investigate other pathology. All MD-
IPMNs and BD-IPMNs with high-risk stigmata should be
considered for resection. BD-IPMNs with “worrisome” stig-
mata require endoscopic ultrasound± fine needle aspiration.
Simple BD-IPMNs even when in excess of 30mm diameter
can be entered into surveillance programs. However, there is
no clear “best modality”, no optimal interval, and no standard
protocol of how to undertake this, with many institutional/
national preferences. In addition, both serum tumor markers
(carcinoembryonic antigen (CEA) and carbohydrate antigen
19-9 (CA19.9))8 and cyst fluid analysis for cytology and/or
tumor markers have been employed in identifying patients at
risk of high-grade dysplasia or invasive cancer,9 although
again there is no universal practice.
As IPMN patients are at risk for developing pancreatic
cancer, timely detection in high-risk groups is of paramount
importance. Current guidelines that provide a framework for
the management of IPMN are based on review of literature.
More objective assessments in the form of systematic reviews
with meta-analyses are limited.10 Furthermore, the two
published meta-analyses11,12 primarily address only imaging
characteristics (cyst size, mural nodule presence, and main
pancreatic duct (MPD) dilation) predictive of malignancy.
The aims of this systematic review were: (1) to assess the
diagnostic modality (computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography
(PET)) with the best rate of detection for malignant change in
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IPMN and (2) the sensitivity and specificity of (i) risk features
on imaging, i.e., mural nodule, cyst size, and main pancreatic
duct dilation, (ii) cyst fluid tumor markers, (iii) serum tumor
markers, and (iv) combination of parameters for detecting
malignant transformation in IPMN.
METHODS
Medline, Embase, and Web of Sciences databases were
searched from November 2006 to March 2014. The start date
of the searches was set to concur with the publication of the
Sendai International Consensus Guidelines. Search terms
were “intraductal papillary mucinous neoplasm” and
“pancreas OR pancreatic OR pancrea*.” Inclusion criteria
were retrospective and prospective studies dealing with IPMN.
Exclusion criteria were case series of ≤ 10 patients and
studies on cystic tumors where data were not separately
available for patients with IPMN. Reference lists of selected
studies were also reviewed for possible additional studies.
Two independent reviewers (A.S. and E.B.) assessed the
abstract of every study identified by the search to determine
eligibility. Blinding to source was not performed. Full articles
were then selected for further assessment if the abstract
suggested the study included patients with IPMN and the
outcomes outlined before. If these criteria were unclear from
the abstract, the full article was retrieved for clarification.
Papers not meeting the inclusion criteria were excluded. Any
disagreements were resolved by discussion. Following study
selection, data extraction was undertaken by two independent
assessors (either A.S. or E.B. and R.J.) and results compared.
Data were extracted on the following parameters: patient
demographics (age, gender), study period, imaging modality
used, details on imaging of cyst size, presence of mural
nodule, MPD size and cutoff used to consider MPD dilated,
type of IPMN, cyst tumor marker levels/cutoff, serum tumor
markers (CEA and CA19-9) levels/cutoff, management
(resection with its details, or surveillance), and in resected
patients details of histology (type of IPMN, and degree of
dysplasia or invasive cancer).
The outcome measures were the sensitivity and specificity
of a diagnostic modality/imaging risk feature for the detection
of suspected high-grade dysplasia and invasive cancer
(termed “malignancy”). Meta-analyses were carried out using
a hierarchical summary receiver operator characteristic
(HSROC) approach.13 This approach calculates the position
and shapes of the receiver operator curve for each diagnostic
test and allows for variability both within and between studies.
This approach allows for the estimated study sensitivity and
specificity to be modeled jointly as opposed to analyzing each
outcome separately and allows for correlation between the
study outcomes to be accounted for. Diagnostic test was
included as a covariate in the model as opposed to using
different models for each test. This was to ensure summaries
account for within-study variability as many studies report on
more than one test. Each type of diagnostic test required a
minimum of four observations to estimate all parameters. Both
CTand MRI are merged into a single modality as there are not
sufficient observations for pooled sensitivity/specificity esti-
mates for each category separately. For the analysis of PET
and CT/MRI features, only a few observations were available
and models were simplified to produce parameter estimates
by assuming constant variance in both the malignant and
nonmalignant populations. Current international consensus
guidelines for the management of IPMN4 do not recommend
endoscopic ultrasound (EUS) routinely, it being reserved for
“worrisome cysts.” Therefore, EUS findings rather than the use
of it as a modality have been modeled.
Model summaries are presented in terms of sensitivity and
specificity estimates with associated 95% credibility intervals
(CIs) for each statistic individually. Graphical summaries are
provided with the joint credibility interval for both sensitivity
and specificity determined by the observed correlation
between model parameters and the size set to contain 95%
of the observed posterior estimates. The area under the curve
(AUC), estimated using Monte Carlo integration are presented
with associated 95% CI is used as a single measure to
compare diagnostic tests.
Publication bias due to sample size was investigated by
plotting the log diagnostic odds ratio (DOR) against the
effective sample size.14,15 Analyseswere carried out using the
statistical packagesWinBUGS16 and results compiled using R
(version 3.01).17 Parameters estimated were obtained via a
Markov chain Monte Carlo) procedure (10,000 draws with a
thin of 20 following burn in and convergence).
Assessment of study quality was done using theQUADAS-2
tool18 utilizing Revman version 5.2 software.19 Study hetero-
geneity is measured via means of Cochrane’s Q statistic on
the log diagnostic odds ratio for each modality separately.
Sensitivity analyses are carried out to assess the effects of
study quality and the effect of individual studies on the study
results. The effect of study bias is assessed by removing all
studies with at least one high-risk element via the QUADAS-2
tool. Influence measures for each study are carried out by
fitting models with each study in turn omitted.
RESULTS
A total of 481 eligible studies were identified, of which 51
studies met the inclusion criteria and 37 of these were
incorporated into meta-analyses (Figure 1). Quality of studies
included in meta-analyses is displayed in Figure 2a. Assess-
ment of bias via a funnel plot is included in Figure 2b and show
no evidence of publication bias (P=0.302).
The pooling of studies from the searches yielded 37
studies, incorporating 4,073 patients whowere included in the
meta-analyses (Table 1). A further 14 (1,156 patients) studies
were included in the systematic review (Table 2), but not in the
meta-analyses because of lack of extractable data.
The included studies were assessed for methodological
quality. A summary of results is presented in Figure 2a. In ac-
cordance with the QUADAS-2 tool, each study was assessed
for bias in four domains: patient selection, index test, reference
standard, and flow/timing.18
Five studies were deemed at high risk of selection bias
because of concerns over the possible use of selective
enrollment rather than a consecutive approach. The “blinding”
of researchers to the reference standard was poorly docu-
mented, leading to an unclear assessment of test review bias
in just a third of cases.20 Similarly, the majority of studies did
not clearly address the possibility of diagnostic review bias
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where prior knowledge of the index test could potentially
influence interpretation of the reference standard.20 In addi-
tion, relatively few studies reported the time interval between
completion of the index test and collection of the reference
standard, resulting in an unclear assessment of disease
progression bias.20 These areas of possible bias could lead to
an overestimation of sensitivity and specificity of the index
tests.21 The applicability of the index tests, reference standard,
and target population was generally high and thought to
correlate well with the review question.
Histology based on resection was available in all included
studies, except one. Sperti et al.22 reported on 64 patients,
with tissue diagnosis available in 47 subjects. In the analyses
on CT/MRI and PETability to detect malignancy, the analyses
were restricted to the 47 patients who had tissue confirmation,
as data for this subset were available. In the analyses on
mural nodule, MPD dilation, and serum CA19-9, the entire
study population was included as subset details were not
available.
Imaging
CT vs. MRI. Two studies23,24 directly compared CTwith MRI
in the diagnosis of IPMN (Table 2), but extractable data were
only available in one study.23 Waters et al.23 retrospectively
Figure 2 Assessments of study quality and bias. QUADAS-2 quality assessment of studies included in (a) meta-analyses and (b) bias.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection.
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Table 1 Studies included in meta-analyses
First author Year Study
period
Number of
patients
Median age in
years
Number of
males
Types of IPMN (number) Number
resected
Sahora52 2013 1995–2012 563 67 232 BD (563) 226
Shimizu34 a 2013 1996–2011 310 67.1 (mean) 181 MD (51), mixed (57), BD (202) 310
Fritz63 2012 2004–2010 123 NA NA BD (123) 123
Hirono35 2012 1999–2011 134 69 (mean) 74 BD (134) 134
Kurihara36 2012 2003–2007 22 68 (mean) 14 MD (6), BD (16) 22
Ohno37 2012 2001–2009 142 65 (mean) 77 BD (142) 30
Ohtsuka38 2012 1990–2010 138 67 (mean) 83 MD (39), BD (99) 138
Akita39 2011 1992–2007 38 63 (mean) 20 BD (38) 38
Cone58 2011 2001–2009 52 65 (mean) 24 NA 52
Fritz8 2011 2004–2008 142 NA 82 MD (16), mixed (75), BD (51) 142
Hwang40 a 2011 1994–2008 237 63 (mean) 137 BD (237) 247
Maguchi41 a 2011 Not
specified
349 66 170 BD (349) 29
Xu61 2011 1999–2008 86 62 (mean) 62 NA 86
Arikawa42 2010 2003–2008 25 65.2 (mean) 20 BD (25) 25
Hong25 2010 2005–2009 31 65 (mean) 15 MD (NA), BD (49) 31
Ingkakul 57 2010 1987–2008 200 NA 108 BD (200) 200
Jing43 2010 1993–2007 39 55 (mean) 39 MD (11), mixed (4), BD (24) 39
Liu44 2010 2001–2008 25 61 14 MD (5), mixed (13), BD (7) 25
Mimura45 2010 1998–2009 82 69 49 MD (39), BD (43) (did not consider
mixed IPMN; classified based on pre-
dominant type into MD and BD)
82
Sadakari53 2010 1987–2008 73 66 48 BD (73) 73
Tomimaru33 2010 2006–2008 29 NA 13 MD (3), mixed (13), BD (13) 29
Correa-
Gallego59
2009 NA 72 NA NA NA NA
Manfredi6 2009 2001–2005 51 62 (mean) 32 MD (29), mixed (22) Nil
Nagai46 2009 1984–2007 84 63 48 BD (84) 84
Ohno47 2009 2001–2007 87 67 (mean) 53 MD (14), mixed (25), BD (48) 87
Tan26 2009 2005–2008 20 62 (mean) 11 MD (3), mixed (12), BD (5) 20
Woo54 2009 1998–2005 190 63(mean) 111 BD (190) 85
Jang48 a 2008 1993–2006 138 61 (mean) 87 BD (138) 138
Maire60 2008 1994–2006 41 64 16 MD (2), mixed (26), BD (13) 41
Ogawa27 2008 2000–2006 61 64.9 (mean) 39 MD (NA), mixed (NA), BD (49) 61
Pitman49 2008 1992–2006 20 68 (mean) 11 BD (20) 18
Takeshita50 2008 2002–2006 46 65 (mean) 28 BD (46), mixed IPMN also grouped
under BD
46
Tang55 2008 1995–2006 31 66.6 (mean) 19 BD (31) 31
Pais62 2007 1992–2006 74 65 38 MD (21), mixed (35), BD (18) 74
Rodriguez51 a 2007 1990–2005 145 67 62 BD (145) 145
Salvia56 b 2007 2000–2003 109 64 45 BD (109) 25
Sperti22 2007 1999–2005 64 64 (mean) 33 MD (28), BD (36) 42
BD, branch duct; IPMN, intraductal papillary mucinous neoplasia; MD, main duct, NA, not available.
aMulticentric study.
bProspective study.
Table 2 Studies included in systematic review only
First
author
Year Study
period
Number of
patients
Median age in years Number of
males
Types of IPMN (number) Number
resected
Bae72 2012 1995–2010 194 63 116 BD (194) 52
Kang73 2011 2000–2009 201 63 (mean) 111 BD (201) 35
Uehara74 2011 NA 100 65 53 BD (100) 1
Zhang28 2011 2004–2009 36 64 (mean) 26 BD (36) 36
Kanno75 2010 1995–2007 159 69 (mean) 96 BD (159) 44
Yamada29 2010 1997–2004 20 72 (mean) 11 MD (3), mixed (16), BD (1) 20
Salvia76 2009 1990–2006 131 67 52 BD (131) 10
Yoon30 2009 2004–2007 21 69 (mean) 7 Mixed (10), BD (11) 21
Manfredi31 2008 2001–2006 26 67 (mean) 10 BD (16) -
Rautou77 2008 1999–2005 121 63 25 BD (121) 2
Tanno78 2008 1990–2006 82 68 57 BD (82) 7
Yamada 32 2008 1997–2004 16 65 (mean) 13 MD (1), mixed (8), BD (7) 16
Waters23 2008 1991–2006 18 66 7 MD (1), mixed (4), BD (13) 18
Song24 2007 2002–2006 31 Not detailed NA Not detailed 31
BD, branch duct; IPMN, intraductal papillary mucinous neoplasia; MD, main duct, NA, not available.
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evaluated CT/magnetic resonance cholangiopancreatogra-
phy data in 18 patients who had all been operated upon
within 12 months of surgery. They found that secretin
magnetic resonance cholangiopancreatography was superior
to multidetector CT (16 and 64 slices) in identifying ductal
connection, main duct involvement, or small cysts from side
branch IPMN. Song et al.24 studied 53 patients following
surgery, of whom 31 were diagnosed as IPMN. MRI did not
include secretin. One reader found the diagnostic accuracy
for IPMN to be better for MRI than CT (0.995 vs. 0.875;
P= 0.10), but the other reader did not concur (0.932 vs.
0.850; P=0.059). Both readers found ductal communication
to be significantly better delineated on MRI compared
with CT.
Prediction of malignancy by CT and/or MRI. Nine studies
were included in the systematic review (295 patients),22,25–32
but meta-analyses could only be performed using data from
four studies (159 patients);22,25–27 Sperti et al.22 evaluated 64
patients with helical CT (2.5mm slices) and 60 patients with
MRI/secretin-stimulated magnetic resonance cholangiopan-
creatography and reported the pooled results. Ogawa et al.27
evaluated contrast-enhanced CT scans of 61 consecutive
resections for IPMN using a multiphase scanner with either 4
or 16 detector rows and reconstruction with 5mm thickness.
The two radiologists were blinded to the findings at surgery/
histology, and consensus of opinion was used to come to a
conclusion. Tan et al.26 employed 4- or 16-slice dual-phase CT
with multiplanar volume reformations or curved reformations.
Two radiologists blinded to the findings at surgery/histology
reviewed the scans, and any difference of opinion was
resolved by seeking input from a third radiologist. Hong
et al.25 used 16 or 64 detector CT, with two radiologists blinded
to results of histology interpreting the scans independently.
The pooled sensitivity of CT/MRI to detect malignancy
(Table 3 and Figure 3) was 0.809 (95% CI 0.714–0.883) and
the specificity was 0.762 (95% CI 0.654–0.851).
Prediction of malignancy by PET. Systematic review and
meta-analysis of 3 studies (106 patients) were undertaken.
Hong et al.26 used a PET scanner with axial field view of
15.7 cm, and maximal standardized uptake value (SUV)
cutoff of 2.5. They opined that PET outperformed CT in
detecting malignant IPMN. Tomimaru et al.33 assessed
different SUVmax levels to differentiate between benign and
malignant IPMNs and found a value of 2.5 to be the best
cutoff. A combination of mural nodule on CT and PET
SUVmax of 2.5 lead to the best yield of detecting malignancy.
Sperti et al.22 performed fludeoxyglucose F 18 (18FDG) PET
using a machine with field view of 16.2 cm, and concluded
that PET (mean SUVmax 4.2; range 2.5–9) was more
accurate than CT and MRI in distinguishing between benign
and malignant IPMNs.
The pooled sensitivity of PET to detect malignancy (Table 3
and Figure 4) was 0.968 (95% CI 0.900–0.995) and the
specificity was 0.911 (95% CI 0.815–0.998).
Prediction of malignancy by presence of mural nodule on
imaging. A total of 21 studies (1,674 patients) evaluated the
association between mural nodule and malignancy.6,22,33–51
Table 3 Imaging and tumor marker characteristics suggestive of malignancy in IPMN (all types)
Characteristic Sensitivity (95%CI) Specificity (95% CI) Area under the curve (95% CI) Q-test for heterogeneity
Presence of risk features on CT/MRI 0.809 (0.714–0.883) 0.762 (0.654–0.851) 0.856 (0.778–0.915) 5.24 (0.15)
Presence of risk features on PET 0.968 (0.900–0.995) 0.911 (0.815–0.998) 0.985 (0.949–0.998) 7.82 (0.02)
Mural nodule presence 0.69 (0.585–0.793) 0.798 (0.722–0.862) 0.819 (0.719–0.925) 21.7 (0.36)
Main pancreatic ductal dilation 0.614 (0.471–0.746) 0.687 (0.564–0.799) 0.702 (0.596–0.838) 7.48 (0.88)
Cyst size43 cm 0.682 (0.575–0.789) 0.574 (0.43–0.702) 0.657 (0.575–0.766) 17.14 (0.004)
Cyst fluid elevated CEA levels 0.636 (0.179–0.926) 0.72 (0.48–0.894) 0.843 (0.481–0.997) 22.41 (0.1)
Elevated serum CEA levels 0.169 (0.074–0.321) 0.933 (0.867–0.972) 0.691 (0.375–0.996) 3.24 (0.78)
Elevated serum CA19-9 levels 0.38 (0.156–0.634) 0.903 (0.846–0.947) 0.729 (0.651– 0.792) 6.05 (0.42)
Combinations 0.743 (0.542–0.9) 0.906 (0.782–0.963) 0.907 (0.701–0.999) 8.34 (0.3)
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; CT/MRI, computed tomography/magnetic resonance imaging;
IPMN, intraductal papillary mucinous neoplasia; PET, positron emission tomography.
Risk features on imaging were presence of mural nodule/septation, cyst size43 cm, main pancreatic duct dilation, and uptake on PET.
Note: numbers represent study detailed in table (inset in figure)
Figure 3 Hierarchical summary receiver operator characteristic (HSROC) curve
of prediction of malignancy by computed tomography/magnetic resonance imaging
(CT/MRI). Note that the numbers represent the studies detailed in table (inset in
figure). The black circles represent the individual study estimate, and vary based on
study size. The blue circle stands for the overall estimate pooling all studies, and the
dotted blue line indicates the 95% credibility interval.
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The pooled sensitivity was 0.69 (95% CI 0.585–0.793)
and specificity was 0.798 (95% CI 0.722–0.862) (Table 3
and Figure 5). Further analyses of the 14 studies
(1,398 patients)34,35,37–42,45–49,51 that dealt exclusively with
BD-IPMN revealed a pooled sensitivity of 0.622 (95% CI
0.506–0.736) and specificity of 0.819 (95% CI 0.709–0.898)
(Table 4 and Figure 6).
There were variations between studies in the definition of
this feature, and the imaging modality used (ultrasound, CT,
MRI, endoscopic retrograde cholangiopancreatography, or
EUS). Eighteen studies considered the presence of mural
nodule as an at-risk feature, whereas in 4 studies the size of
the mural nodule was considered. Two studies used a 5mm
cutoff,34,35 one used 7mm,22 and another 10mm.41
Prediction of malignancy by cyst size on imaging. The
association of cyst size with malignancy was assessed in
16 studies (1,217 patients).33,35,38,39,41,44–46,48,50–56 The
pooled sensitivity was 0.682 (95% CI 0.575–0.789) and
specificity was 0.574 (95% CI 0.43–0.702) (Table 3 and
Supplementary Figure S1 online). Twelve of these studies
(898 patients)26,35,38,39,41,45,46,51,53–56 were limited to BD-
IPMN, and here the pooled sensitivity was 0.671 (95% CI
0.527–0.804) and specificity was 0.574 (95% CI 0.413–0.722)
(Table 4 and Supplementary Figure S2). The majority of studies
used 3 cm as cutoff (12 studies), whereas 2 cm was used in
two studies44,48 and 3.5 cm in one study.56 Again, a variety of
imaging methods (ultrasound, CT, MRI, endoscopic retrograde
cholangiopancreatography, or EUS) were used.
Prediction of malignancy by MPD dilation on imaging. A total
of 14 studies (935 patients) assessed the prediction of
malignancy on MPD dilation.6,22,27,33,35,38,39,41,44–46,50,53,57
The pooled sensitivity was 0.614 (95% CI 0.471–0.746)
and specificity was 0.687 (95% CI 0.564–0.799) (Table 3
and Figure 7). Eight of these studies looked at BD-IPMN
Note: numbers represent study detailed in table (inset in figure)
Figure 4 Hierarchical summary receiver operator characteristic (HSROC) curve
of prediction of malignancy by positron emission tomography (PET) scan. Note that
the numbers represent the studies detailed in table (inset in figure). The black circles
represent the individual study estimate, and vary based on study size. The blue circle
stands for the overall estimate pooling all studies, and the dotted blue line indicates
the 95% credibility interval.
Note: numbers represent study detailed in table (inset in figure)
Figure 5 Hierarchical summary receiver operator characteristic (HSROC) curve
of prediction of malignancy by mural nodule on imaging (all intraductal papillary
mucinous neoplasia (IPMN) types). Note that the numbers represent the studies
detailed in table (inset in figure). The black circles represent the individual study
estimate, and vary based on study size. The blue circle stands for the overall estimate
pooling all studies, and the dotted blue line indicates the 95% credibility interval.
Table 4 Imaging and tumor marker characteristics suggestive of malignancy in BD-IPMN
Characteristic Sensitivity (95% CI) Specificity (95% CI) Area under the curve (95% CI) Q-test for heterogeneity
Mural nodule presence 0.622 (0.506–0.736) 0.819 (0.709–0.898) 0.749 (0.644–0.888) 14.79 (0.32)
Main pancreatic ductal dilation 0.508 (0.317–0.697) 0.747 (0.539–0.911) 0.629 (0.507–0.815) 4.05 (0.99)
Cyst size43 cm 0.671 (0.527–0.804) 0.574 (0.413–0.722) 0.662 (0.563–0.783) 8.43 (0.75)
Elevated serum CEA levels 0.129 (0.047–0.286) 0.943 (0.824–0.99) 0.530 (0.241–0.987) 0.93 (0.97)
Elevated serum CA19-9 levels 0.267 (0.079–0.513) 0.928 (0.809–0.989) 0.724 (0.378–1.000) 3.4 (0.64)
BD-IPMN, branch duct intraductal papillary mucinous neoplasia; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval;
PET, positron emission tomography.
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(679 patients)35,38,39,41,45,46,53,57 and in this subgroup the pooled
sensitivity was 0.508 (95% CI 0.317–0.697) and specificity was
0.747 (95% CI 0.539–0.911) (Table 4 and Figure 8).
There were four different cutoff levels used to consider the
MPD dilated. Two studies22,27 used 10mm as the cutoff, 7 mm
was employed in four studies,33,38,39,44 6 mm in a further
four,41,45,46,57 and 5mm in three studies.35,50,53 The cutoff
points of Manfredi et al.6 were 5mm in the head, 4 mm in the
body, and 3mm in the tail of pancreas.
Cyst fluid tumor markers. Six studies35,49,55,58–60 (270
patients) looked at cyst fluid tumor marker levels and their
correlation with malignancy. All studies assessed cyst fluid
CEA levels, and were assessed in meta-analysis. Only one
study assessed CA 72–4 (ref. 54) and two CA19-9 (refs. 50,
54) and hence were not included in the meta-analysis. The
overall pooled sensitivity was 0.636 (95% CI 0.179–0.926)
and specificity was 0.72 (95% CI 0.48–0.894) (Table 3 and
Supplementary Figure S3). None of the studies provided data
for the BD-IPMN subset.
Cyst fluid sample for tumor marker estimation was obtained
at EUS in all but one study,35 where the cyst fluid sample was
taken at endoscopic retrograde cholangiopancreatography.
Four different cutoff levels for cyst fluid CEA were used in the
six studies. Themost common onewas 200 ng/ml employed in
three studies.38,53,54
Serum tumor markers. Nine studies (975
patients)8,22,35,38,40,53,56,57,61 looked at serum CA19-9 levels,
and 6 of these studies (689 patients) evaluated
BD-IPMNs.35,38,40,53,56,57 The overall pooled sensitivity for
all IPMN types was 0.380 (95% CI 0.156–0.634) and
specificity was 0.903 (95% CI 0.846–0.947) (Table 3 and
Figure 9). The overall pooled sensitivity for BD-IPMN was
0.267 (95% CI 0.079–0.513) and specificity was 0.928
(95% CI 0.809–0.989) (Table 4 and Supplementary Figure
S4). The majority of studies (n=7) used a cutoff value of
37 KU/l, though one study used 25 KU/l,62 and in one study
the cutoff value was not specified.35
Seven studies (890 patients)8,35,38,40,53,57,61 assessed serum
CEA levels and 5 of these studies (662 patients) evaluated
BD-IPMN.35,38,40,53,57 The overall pooled sensitivity for all IPMN
types was 0.169 (95% CI 0.074–0.321) and specificity was
0.933 (95% CI 0.867–0.972) (Table 3 and Supplementary
Figure S5). The overall pooled sensitivity for BD-IPMN was
0.129 (95% CI 0.047–0.286) and specificity was 0.943 (95% CI
0.824–0.99) (Table 4 and Supplementary Figure S6). Cutoff
levels varied between studies, and in two studies35,57 the cutoff
was not specified. Three studies8,61 used a cutoff of 5 μg/l, one
study53 used 4 μg/l and another study38 2.3 μg/l.
Combinations of predictors. Seven studies26,27,35,50,54,56,63
encompassing 400 patients pooled combinations of para-
meters to assess their ability to predict malignancy. The overall
pooled sensitivity was 0.743 (95% CI 0.542–0.9) and specificity
was 0.906 (95% CI 0.782–0.963) (Table 3 and Figure 10).
Salvia et al.56 considered the presence of mural nodule or
thick walls and septae as suspicious radiological features, Tan
et al.26 combined mural nodule and thick septae, and Woo
et al.54 combined mural nodule and thick wall. Fritz et al.63
Note: numbers represent study detailed in table (inset in figure)
Figure 6 Hierarchical summary receiver operator characteristic (HSROC) curve
of prediction of malignancy by mural nodule on imaging for branch duct intraductal
papillary mucinous neoplasia (IPMN). Note that the numbers represent the studies
detailed in table (inset in figure). The black circles represent the individual study
estimate, and vary based on study size. The blue circle stands for the overall estimate
pooling all studies, and the dotted blue line indicates the 95% credibility interval.
Note: numbers represent study detailed in table (inset in figure)
Figure 7 Hierarchical summary receiver operator characteristic (HSROC) curve
of prediction of malignancy by main pancreatic duct (MPD) dilation on imaging (all
intraductal papillary mucinous neoplasia (IPMN) types). Note that the numbers
represent the studies detailed in table (inset in figure). The black circles represent the
individual study estimate, and vary based on study size. The blue circle stands for the
overall estimate pooling all studies, and the dotted blue line indicates the 95%
credibility interval.
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used serum CA19-9 and serum CEA in the combination.
Hirono et al.35 employed a combination of mural nodule
45mm present on EUS/CT, and raised CEA in pancreatic
juice obtained at endoscopic retrograde cholangiopancreato-
graphy. Ogawa et al.27 used a combination of the presence of
mural nodule and abnormal attenuating area in surrounding
pancreas parenchyma. Two different combinations were
assessed by Takeshita et al.,50 one being MPD dilation and
presence of mural nodule, and the other MPD dilation and cyst
size 43mm. Data were not extractable on the BD-IPMN
subset.
Based on these studies the most valuable combination for
estimating malignant transformation would appear to be mural
nodule (pooled sensitivity 0.690; 95% CI 0.585–0.793) and
serum CA19-9 (pooled specificity 0.903; 95% CI 0.846–
0.947).
Sensitivity analysis. Results of the sensitivity analysis are
included in the Supplementary Materials. Influence measures
for each study are given in Supplementary Figure S7. They
show that the effect of each individual study is relatively
small. The biggest effects are observed for diagnostic
categories with the fewest data items and greater variability
such as the CEA category; however, even here the effects
of each study are small. Further sensitivity analyses
are carried out that remove any study that is attributed a
“high-risk” score for any component of the QUADAS-2 tool. A
Note: numbers represent study detailed in table (inset in figure)
Figure 8 Hierarchical summary receiver operator characteristic (HSROC) curve
of prediction of malignancy by main pancreatic duct (MPD) dilation on imaging for
branch duct intraductal papillary mucinous neoplasia (IPMN). Note that the numbers
represent the studies detailed in table (inset in figure). The black circles represent the
individual study estimate, and vary based on study size. The blue circle stands for the
overall estimate pooling all studies, and the dotted blue line indicates the 95%
credibility interval.
Note: numbers represent study detailed in table (inset in figure)
Figure 9 Prediction of malignancy by serum carbohydrate antigen 19-9 (CA19-9)
levels (all intraductal papillary mucinous neoplasia (IPMN) types). Note that the
numbers represent the studies detailed in table (inset in figure). The black circles
represent the individual study estimate, and vary based on study size. The blue circle
stands for the overall estimate pooling all studies, and the dotted blue line indicates
the 95% credibility interval.
Combination details: A= mural nodule; B= thick wall and/or septae; C= MPD dilation; D= cyst size 
>3mm; E= serum CA19-9 &CEA; F= raised cyst fluid CEA; G= abnormal area in pancreas 
Figure 10 Prediction of malignancy by combinations of predictors. Note that the
details of the different combinations used in each study are displayed in column 2 of
the table inset into the figure. Each letter represent the following characteristic: A,
mural nodule; B, thick wall and/or septae; C, MPD dilation; D, cyst size43 mm; E,
serum CA19-9 and CEA; F, raised cyst fluid CEA; G, abnormal area in pancreas. The
numbers represent the studies detailed in the table. The black circles represent the
individual study estimate, and vary based on study size. The blue circle stands for the
overall estimate pooling all studies, and the dotted blue line indicates the 95%
credibility interval. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic
antigen; MPD, main pancreatic duct.
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total of 11 studies are removed for this analysis and the
results are included in Supplementary Table S1. The results
obtained here do not differ substantially from those presented
in Table 3.
DISCUSSION
We have adopted a novel approach by using HSROC
curves to compare variations in diagnostic threshold; this
is commonly demonstrated when different definitions are
used in studies for features found in imaging and tumor
markers. The HSROC method also allows for both within-
and between-study variability of sensitivity and specificity
(i.e., random effects), and their possible correlations aswell as
the precision of these estimates within a study.64 The two
existing meta-analyses11,12 used DORs to pool studies. The
drawback with this approach is the inability of DOR to
simultaneously deal with two outcomes, i.e., sensitivity and
specificity. In addition, DORs are difficult to interpret clinically,
and in practice DOR is reasonably constant regardless of the
diagnostic threshold.65
This work has reviewed the risk of malignant transformation
in all IPMNs, and wherever possible, the BD-IPMN subset;
it is restricted to studies subsequent to the Sendai guide-
lines publication. Although Anand et al.12 also included
all IPMN types, no subgroup analysis was performed,
whereas the review by Kim et al.11 was confined to
BD-IPMNs; in reality, only 9 of 23 studies dealt with
BD-IPMNs. On quality assessment, the majority of studies
in our review had high to unclear risk of bias in terms of
patient selection, index test used, and flow/ timing, but had
low risk of bias for features dealing with applicability concerns.
This is because all but one study was retrospective. In
contrast to the meta-analyses of Kim et al.11 that concluded
that all their included (n=23) studies satisfied ≥5 of the
total 7 points on quality assessment, in our study just 16% (6/37)
met ≥5 points. Anand et al.12 did not comment on study quality.
PET shows the most promise as a technique in determining
malignant transformation within IPMN; accepting that there
are only three reports and the overall sample size is small. The
study by Hong et al.25 noted that SUVmax was significantly
higher in malignant IPMNs, with a mean of 6.7 and s.d. of 3.6
compared with benign IPMN (mean 2.1 and s.d. 1). Tomimaru
et al.33 assessed different SUVmax levels to differentiate
between benign and malignant IPMNs; importantly, a correla-
tion between the grade of dysplasia, with high-grade
dysplastic lesions having higher SUVmax than low/moder-
ate-grade dysplasia, was noted. Overall, a combination of
mural nodule on CT and PET SUVmax of 2.5 led to the best
yield of detecting malignancy. This was supported by Sperti
et al.22 who concluded that PET (mean SUVmax 4.2; range
2.5–9) was more accurate than CT and MRI in distinguishing
between benign and malignant IPMNs. Notes of caution must
be raised: when interpreting PET scan, SUV can be affected
by tumor size, patient weight, and blood glucose level, as also
the potential of differing results between different scanners.
False positive values can also occur in the presence of acute
and chronic pancreatitis, and if endoscopic interventions on
the pancreas are performed before PET. Overall, the
sensitivity, specificity, and AUC (95% CI) for PET was 0.968
(0.900–0.995), 0.911 (0.815–0.998), and 0.985 (0.949–
0.998), Table 3. We await the report of the ongoing (closed
to recruitment) PET-PANC trial (http://public.ukcrn.org.uk/
search/StudyDetail.aspx?StudyID=8166) that has evaluated
the role of PET CT in pancreatic cancer.
The benefit of CT vs. MRI in predicting malignancy within
IPMN was not confirmed by this systematic review; however,
these technologies have advanced dramatically over time,66,67
such that modern contrast agents (and secretin stimulation)
provide better images than earlier techniques.68–70 Overall the
sensitivity, specificity, and AUC (95%CI) for CT/MRI are 0.809
(0.714–0.883), 0.762 (0.654–0.851), and 0.856 (0.778–
0.915). Although analysis of CT vs. MRI was not possible,
these data support a trial of direct comparison of modern
contrast-enhanced CT vs. secretin-stimulated magnetic reso-
nance cholangiopancreatography.
We did not specifically look at EUS as it is not used for first-
line imaging, but instead employed to evaluate in greater detail
suspicious features reported on screening investigations.
In our meta-analyses, the presence of a mural nodule
on cross-sectional imaging had good specificity and sensitivity
for predicting malignancy in all IPMNs (sensitivity 0.69;
specificity 0.798; AUC 0.819, see Table 3), as well as in
BD-IPMN (sensitivity 0.622; specificity 0.819; AUC 0.749, see
Table 4), and performed the best compared with all other
parameters, with the exception of when parameters were
combined.
We have demonstrated poor performance of cyst fluid CEA
as a discriminator between benign and malignant IPMNs. The
utility of a raisedCEA only identifies the presence ofmucin and
the implied risk of malignant transformation of mucinous
lesions (IPMN or mucinous neoplasms). Concentrating on
studying novel molecular/proteomic markers in cyst fluid may
shed light on a better predictor.
Serum tumor markers were highly specific but poor on
sensitivity in meta-analyses of all IPMN and BD-IPMN
subsets. However, serum CA19-9 was significantly raised in
patients with invasive cancer, but not high-grade dysplasia,8,61
as also CEA.8 The majority of studies either combined HGD
with invasive cancer35,38,53,57 or the numberswere too small to
draw a meaningful conclusion.22,40,56 This implies, from the
available evidence, that CA19-9 is highly specific for invasive
cancer in IPMN, and would be a useful adjunctive tool.
Discovery of more sensitive biomarkers that can discriminate
malignant transformation are needed.
Combinations of parameters performed the best on meta-
analyses, having the highest pooled sensitivity, specificity
0.743 (0.542–0.900); 0.906 (0.782–0.963); and AUC 0.907
(0.701–0.999), for detection of malignancy within IPMN;
although several combinations were used across the eight
studies. Mural nodule presence along with another parameter
were assessed in six of these studies. Correa-Gallego et al.71
have developed a preoperative nomogram using data on 219
resected IPMN. Male gender, a history of weight loss and
previous malignancy, and presence of a solid component on
imaging conferred increased risk of malignancy in patients
with main/mixed duct IPMN. In BD-IPMN, factors that raised
the risk of malignancy were a history of weight loss, presence
of a solid component of imaging, and cyst size. Future
prospective studies assessing multiple parameters and using
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externally validated predictive nomograms to ascertain risks
may be a way forward.
The model used to synthesize the data, while allowing for
study heterogeneity, did not take any direct account of the
different cutoff values or definitions used for each modality
because of the large variability that was observed. Although
study heterogeneity was not highlighted as a main cause for
most modality, increasing standards of reporting would allow
for a more concise review of the data and would be of clinical
interest.
In conclusion, these systematic review/meta-analyses
suggest elevated serum CA19-9 levels and presence of mural
nodule to be the stand-alone features strongly correlated with
malignancy. Recommending one modality over another for
diagnosis is difficult based on the available literature, and
although PET scanning has promise, it requires evaluation in
larger studies with improved quality.
Future directions. In future, prospective longitudinal studies
using standardized imaging (CT/MRI) with uniform definitions
for risk features to allow comparability between studies are
needed. Comparative studies evaluating CT vs. MRI, and
PET vs. CT/MRI, may help shed light on the optimal imaging
approach. Combining risk features on history, imaging, and
tumor markers in both serum and cyst fluid, as well as
investing in the efforts to discover/validate novel biomarkers,
may help refine the at-risk group, improving the specificity of
current guidelines and sparing unnecessary surgery for those
with low- to moderate-grade dysplasia.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Guidance exists on which intraductal papillary mucinous
neoplasias (IPMNs) should undergo immediate resection
and which should be screened.
✓ Modality and interval of screening is ad hoc between
centers and health-care environments.
WHAT IS NEW HERE
✓ Current literature cannot determine whether computed
tomography (CT) vs. magnetic resonance
cholangiopancreatography (MRCP) has superiority in
identifying malignant transformation.
✓ Positron emission tomography (PET) appears highly
sensitive and specific in determining malignant
transformation; further evaluation is needed.
✓ Combining stigmata shows the best, pooled sensitivity and
specificity for prediction of malignant transformation.
✓ Mural nodules are highly sensitive, whereas serum
carbohydrate antigen 19-9 (CA19-9) is highly specific for
malignancy.
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